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Hyperexpression of the granzyme B inhibitor PI-9 in human
renal allografts: A potential mechanism for stable renal function
in patients with subclinical rejection.
Background. Granzyme B–positive T lymphocytes infiltrate
renal allografts during acute cellular rejection and cause graft
injury by inducing apoptosis of tubular cells. Protease inhibitor 9
(PI-9), an intracellular serpin that inhibits granzyme B, is known
to protect cells from the action of cytotoxic T lymphocytes.
Methods. Expression of granzyme B and PI-9 in transplant
biopsies from patients with acute cellular rejection (N = 18),
subclinical rejection showing a mononuclear cell infiltrate with-
out deterioration of renal function (N = 15), or stable trans-
plant function (N = 13) were studied. Immunohistochemical
stainings were analyzed and scored semiquantitatively by two
independent observers who were not aware of clinical results.
Results. Granzyme B was expressed by mononuclear cells in
all biopsies with cellular infiltrates. PI-9 was diffusely expressed
by tubular cells in the allografts of all patients with subclinical
rejection. In contrast, PI-9 expression was only focally in the
patients with clinical rejection or without rejection. Although
no difference was observed in granzyme B levels between acute
and subclinical rejection, in subclinical rejection tubular epithe-
lial cells showed significantly stronger expression of PI-9 than
in acute rejection (P = 0.011).
Conclusion. These data suggest that a high expression of PI-9
by tubular epithelial cells can serve as one of the factors pro-
tecting renal allografts from rejection in spite of the presence
of inflammatory cell infiltrates.
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Acute renal allograft rejection is characterized by in-
filtrating cytotoxic T cells in the graft which can induce
apoptosis of renal tubular epithelial cells. The latter can
occur via two pathways, one dependent on exocytosis of
cytotoxic granules containing granzymes A and B, which
are delivered into a target cell via transmembrane pores
formed by perforin, the other involving death receptor–
induced apoptosis such as the CD95 ligand/CD95
pathway.
Previous studies have demonstrated that granzyme B–
positive cytotoxic T cells are mainly responsible for de-
struction of tubular epithelial cells during acute cellular
rejection in human renal allograft recipients [1–3]. In-
deed, measurement of mRNA encoding granzyme B or
perforin in urinary cells constitutes a noninvasive diag-
nostic tool to assess allograft rejection, and also urinary
levels of these molecules predict the occurrence of such
an episode, although with moderate sensitivity [1]. The
intracellular serpin protease inhibitor 9 (PI-9) is the only
known human protein that specifically inhibits granzyme
B activity and cells transfected with PI-9 are protected
against granzyme B–induced apoptosis [4, 5]. The in vivo
distribution of PI-9 also suggests that a main function of
this inhibitor is to protect cells against unwanted cytotox-
icity by granzyme-expressing cells, since PI-9 is among
others expressed at immune privileged sites [6]. PI-9 is
also expressed by malignant lymphomas and presumably
serves to protect the tumor from elimination by cytotoxic
lymphocytes [7, 8].
Mononuclear infiltrates are frequently found in renal
transplant biopsy specimens from patients with deteri-
orating renal function. In particular, the expression of
granzyme B by these mononuclear cells is associated with
acute allograft rejection. However, the presence of cy-
totoxic infiltrates in allografts does not always lead to
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overt rejection. The prevalence of such infiltrates in al-
lografts of patients without deteriorating renal function,
so-called subclinical rejection is estimated as 30% to 42%
during the first 3 months after transplantation [9–11].
A molecular explanation for this apparent resistance of
the allograft against the action of cytotoxic cells is, how-
ever, lacking. We hypothesized that expression of PI-9 in
tubular epithelial cells in the infiltrated allograft may con-
stitute a mechanism to resist granzyme B–induced apop-
tosis. To test this hypothesis, we studied the expression of
granzyme B in relation to that of PI-9 in renal allograft
biopsies obtained from patients with subclinical rejection
in comparison to acute rejection.
METHODS
Renal allograft biopsies
Renal allograft biopsy specimens were obtained from
patients who participated in a study in which biopsies
were taken at 6 months after transplantation according
to protocol, or upon clinical indication. According to this
protocol, all renal transplant recipients of a first or second
graft, except for highly immunized patients with panel
reactive antibodies >80%, were prospectively random-
ized to once daily versus twice daily dose tacrolimus or
cyclosporine in order to detect possible structural and
functional differences at 6 months and 12 months after
transplantation by prescheduled biopsies and glomerular
filtration rate (GFR) measurements. The protocol had
been approved by the Medical Ethical Committee and
each patient had given written informed consent. All pa-
tients were matched for gender, age, and the number of
human lymphocyte antigen (HLA) mismatches. There
were no significant differences in immunosuppressive
regimen between patients in different clinical settings.
In 15 biopsies, subclinical rejection, defined as the pres-
ence of histologic signs of rejection (tubulitis) without
deterioration of renal function, was detected. Eighteen
biopsies from patients with acute rejection were studied
as well. Histologic diagnosis was made according to the
Banff classification [12]. Subclinical rejections were all
graded as type IA. Acute rejection type IA was detected
in five biopsies, acute rejection type IB in three biopsies,
acute rejection type IIA in four biopsies, and acute rejec-
tion type III in six biopsies. Thirteen patients without any
histologic abnormality in the allograft biopsy obtained
at 6 months after transplantation and with stable renal
function served as a control group (“no rejection”). All
patients survived the first year after transplantation. Pa-
tients with subclinical rejection didn’t experience acute
clinical rejection later on up to 1 year posttransplanta-
tion. Patients with subclinical rejection showed a trend
towards less function as appeared by calculated creati-
nine clearance at 12 months in comparison with patients
with no rejection (P = 0.05). However, at 3 months, no
significant difference in renal function was detectable be-
tween these groups. Patients with subclinical rejection
had a better graft function at 3 months as compared to
patients with acute rejection, which difference was not
present anymore at 12 months (P = 0.003 and P = 0.49,
respectively). At 3 and 12 months, patients with acute re-
jection had significantly decreased renal function as com-
pared to patients with no rejection (P = 0.002 and P =
0.03, respectively).
Antibodies
Monoclonal antibodies used were PI-9-17, which is a
mouse IgG1 monoclonal antibody against PI-9, and mon-
oclonal antibody GB7, an IgG2a monoclonal antibody
against granzyme B. These monoclonal antibodies were
produced and purified as described previously [6, 13].
Immunohistochemical staining procedures
Tissue slides were processed routinely by fixation in
10% formalin for 18 hours and subsequently embed-
ded in paraffin. Four micrometer thick sections were
mounted on poly-L-lysine–coated slides. Endogenous
peroxidase activity was blocked by incubation for 30 min-
utes with 0.3% (vol/vol) H2O2 in methanol. Tissue sec-
tions were subjected to antigen retrieval by boiling in
0.01 mol/L sodium-citrate (pH 6) for 10 minutes in a mi-
crowave oven. Sections were stained for PI-9 with pu-
rified monoclonal antibody PI-9-17 at 2.5 lg per mL,
and for granzyme B with GB7 at 1.2 lg per mL. The
secondary antibody was biotinylated rabbit antimouse
F(ab)2 Ig, 1:500. These secondary antibodies were de-
tected with avidine-biotin-horseradish peroxidase (HRP)
complex (ABC). Bound antibodies were visualized by
incubation with diaminobenzidine/H2O2. Slides were
slightly counterstained with methyl green. Negative con-
trol slides were stained with mouse IgG of the appropri-
ate subclass. Positive control slides were tissue sections
from lymph node with diffuse large B-cell non-Hodgkin
lymphoma. Apoptotic cells were detected with the use
of an anti-[active caspase 3] antibody (Cell Signaling
Technology, Beverly, MA, USA) and revealed with a
polymerized HRP-conjugated goat antirabbit IgG anti-
body (PowervisionTM) (Immunovision Technology, Daly
City, CA, USA). Double immunostaining for CD3 and
PI-9, granzyme B and PI-9, CD10 and PI-9, and Tamm-
Horsfall and PI-9 was performed using anti-PI-9 and, re-
spectively, rabbit polyclonal anti-CD3 antibody (Dako,
Glostrup, Denmark), GB7, mouse monoclonal IgG1 anti-
CD10 antibody (Neomarkers, Fremont, CA, USA), and
sheep polyclonal anti-Tamm-Horsfall (Campro Scien-
tific, Veenendaal, The Netherlands). The anti-PI-9 an-
tibody was probed with a secondary goat antimouse
IgG1-AP antibody (Southern Biotechnology Associates,
Birmingham, AL, USA), CD3 antibody was probed
with a polymerized HRP-conjugated goat antirabbit IgG
antibody (PowervisionTM), GB7 antibody was probed
with a secondary goat antimouse IgG2a-HRP (Southern
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Biotechnology Associates), CD10 antibody was probed
with a secondary goat antimouse IgG1-HRP (Southern
Biotechnology Associates), and Tamm-Horsfall antibody
was probed with a secondary rabbit antisheep IgG anti-
body (Dako). Activated protein (AP) activity was visu-
alized with Vector Blue and HRP activity with Novared
(Vector Laboratories, Burlingame, CA, USA).
Scoring was performed independently by two ob-
servers (S.F. and A.T.R.). The pathologist and a member
of the clinical team examining the tissue slides were not
aware of clinical diagnosis and outcome. In fact, this was
a secondary review of biopsies and not the first clinical
review leading to the choice of treatment which has been
performed by another pathologist. The immunostainings
were quantified using a semiquantitative scoring system.
This scoring system used four different degrees to deter-
mine the intensity and extent of expression of either PI-9
or granzyme B as measured by the percentage of posi-
tive tubules for PI-9 and by number of cells positive for
granzyme B, respectively. For PI-9 the scoring system was
as follows: 0, negative staining; 1, weak expression (0%
to 25% of tubuli); 2, mild expression (25% to 50% of
tubuli); 3, moderate expression (50% to 75% of tubuli);
and 4, strong expression (>75% of tubuli). For granzyme
B the scoring system was as follows: 0, <5 cells/× 400; 1, 5
to 25 cells/× 400; 2, 26 to 50 cells/× 400; 3, 51 to 75 cells/×
400; and 4, >75 cells/× 400.
Statistical methods
Given the ordinal nature of our measurements, we used
chi-squared test for trend to analyze the differences in
expression of PI-9 in tubular epithelial cells and that of
granzyme B by cytotoxic T cells in different clinical con-
ditions. Differences in the number of preserved tubules,
the number of apoptotic cells and in creatinine clearance
between different clinical conditions were assessed by
Kruskal-Wallis one-way analysis of variance (ANOVA)
test. P values below 0.05 were considered as significant.
RESULTS
Infiltrating cytotoxic cells in the allograft
express granzyme B
Granzyme B was expressed by infiltrating CD3+ lym-
phocytes in all renal biopsy specimens showing an inflam-
matory cell infiltrate, irrespective of the clinical diagnosis.
Examples of granzyme B expression are given in Figure 1.
The median score for the number of granzyme B–positive
cells was +2.5 [range (0.0) to (+4.0)] in cases of acute re-
jection versus +2.0 [range (+1.0) to (+3.0)] in subclinical
rejection (P = 0.10) (see Fig. 2). Biopsies with stable re-
nal function displayed hardly any granzyme B–positive
cells [median score 0.0 range (0.0) to (+1.0)]. Double
immunostaining with granzyme B and PI-9, and PI-9 and
CD3 showed that infiltrative lymphocytes were positive
for both granzyme B and PI-9, which is consistent with
Fig. 1. Expression of protease inhibitor (PI-9) by renal tubular cells
and expression granzyme B by cytotoxic T cells in different clinical
conditions. Expression of PI-9 by renal tubular cells; no rejection with
stable renal function (A), acute rejection (C), and subclinical rejection
(E). Expression of granzyme B by cytotoxic T cells; no rejection with
stable renal function (B), acute rejection (D), and subclinical rejection
(F). Immunostaining for PI-9 of diffuse large B-cell non-Hodgkin’s lym-
phoma is shown as positive control (G). Representative negative con-
trol consisting of a renal biopsy stained with an irrelevant mouse IgG1
monoclonal antibody (H) (original magnification ×20).
previously published data [4, 5]. Given the semiquanti-
tative nature of histopathologic studies one cannot mea-
sure the expression levels of granzyme B and PI-9 exactly.
However, striking differences in PI-9 and granzyme B ex-
pression by T cells in biopsies with acute rejection versus
subclinical rejection were not observed.
PI-9 expression by allograft tubular epithelial cells in
subclinical rejection is higher than in clinical rejection
PI-9 was diffusely expressed by tubular cells in the al-
lografts of all patients with subclinical rejection as shown
by double immunostaining with PI-9 and Tamm-Horsfall
protein, and PI-9 and CD10 (see Fig. 2). In contrast, PI-9
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Fig. 2. Double immunostaining for protease inhibitor (PI-9) (blue)
and granzyme B (red) (A), CD3 (red) (B), Tamm-Horsfall protein (red)
(C), and CD10 (red) (D). Arrows show double positive immunoreac-
tivity (purple) [original magnification ×60 for (A and B) and ×20 for
(C and D)].
expression was only focally in an intracellular inhomo-
geneous pattern in most patients with clinical rejection
and patients without rejection. Also, some interstitial
PI-9 staining was here evident which is probably asso-
ciated with granzyme B–positive cells. Examples of PI-9
expression in the allografts are shown in Figure 1. As il-
lustrated in Figure 3, the extent of PI-9 expression was
higher in the patients with subclinical rejection [median
score +2.0, range (+1.0) to (+3.0)] than in the patients
with acute rejection (median score of +1.0, range (0.0)
to (+3.0)] (P = 0.011). PI-9 median score in no rejec-
tion specimens with stable renal function was +1.0 [range
(0.0) to (+3.0)]. PI-9 expression in subclinical rejections
as compared to no rejections was also significantly higher
(P = 0.014). To exclude a more extensive tubular destruc-
tion in biopsies with florid rejection as a cause of biased
decreased PI-9 expression in biopsies with acute rejection
versus subclinical rejection, we measured the number of
preserved tubules in five acute, five subclinical, and five
“no rejection” biopsies by calculating the average num-
ber of tubules in five separate power fields (original mag-
nification ×40) per biopsy by two independent observers.
In order to clearly identify the tubular basement mem-
brane we used Sirius red stainings. Then, Kruskal-Wallis
one-way ANOVA analysis of these data was performed.
The number of preserved tubules in acute rejections and
subclinical rejections was not significantly different (P =
0.76). In order to compare the frequency of apoptosis of
tubular cells, we quantified the number of apoptotic cells
stained with anti-[active caspase 3] antibody. Although
no significant differences were observed in the number
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Fig. 3. The number of granzyme B–positive cytotoxic T cells (closed
symbols) and expression of protease inhibitor (PI-9) by renal tubular
cells (open symbols) in renal allografts from patients with different clin-
ical outcome. Expression was quantified as a score, which is explained
in the Methods section.
of apoptosis in relation to the expression degree of PI-9
showed a trend toward higher in acute rejections as com-
pared to subclinical rejections and no rejections (data not
shown).
DISCUSSION
A number of studies have demonstrated that the pres-
ence of granzyme B–expressing cytotoxic cells in renal
allografts of patients with kidney transplantation is in-
dicative for acute rejection [1–3]. In the present study, we
addressed the role of PI-9, a specific inhibitor of granzyme
B as one of the protective forces against granzyme B–
mediated immunologic allograft injury in subclinical re-
jection. Patients with subclinical rejection have a stable
renal function in spite of cytotoxic infiltrates expressing
granzyme B in their allograft. Here, we show that PI-9 ex-
pression by allograft tubular epithelial cells in subclinical
rejection is higher than in clinical acute rejection. High
PI-9 expression in these tubules correlates with the pres-
ence of granzyme B–positive T lymphocytes. These data
point to a protective role of PI-9 against cytotoxic T cells
in human renal allografts.
Until recently, subclinical rejection episodes defined as
the presence of a mononuclear infiltrate and other histo-
logic signs of rejection in an allograft with stable graft
function were often overlooked, because allograft biop-
sies were performed only if clinically indicated (i.e., in
case of diminished graft function). Per-protocol biopsy
studies have now demonstrated that subclinical rejection
is a common problem which is detected in about 37% of
biopsy specimens obtained at 6 to 12 months and in about
12% to 20% of those obtained thereafter [9–11, 14]. Al-
though in the past years short-term survival of renal allo-
grafts has improved, long-term graft survival has lagged
behind. Acute rejection episodes are considered as an im-
portant predictor of chronic rejection which is considered
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as the most common cause of long-term graft failure [15–
18]. Subclinical rejection is increasingly recognized as an
important risk factor for chronic rejection [10, 11, 14, 19].
Nankivell et al [11] clearly showed that among 114 pa-
tients having two biopsies between 1 and 12 months after
transplantation, moderate chronic allograft nephropathy
(CAN) was evident in 25.6% of biopsy specimens with
previous evidence of subclinical rejection as compared
with 7.5% of those without rejection (P < 0.05). Shishido
et al [14] evaluated 124 sequential protocol biopsies of 46
patients at 2, 3, and 5 years after transplantation who had
already signs of CAN at 1 year. Subclinical rejection was
evident in association with CAN in 50%, 32%, 19%, and
16% of cases with CAN at 1, 2, 3, and 5 years, respectively.
Furthermore, patients with repeated subclinical rejection
in the sequential follow-up biopsies had a lower creati-
nine clearance at 5 years after transplantation and worse
long-term graft survival. Now, studies are needed with
protocol biopsies guiding early interventional therapy to
clarify whether such a treatment has beneficial effects on
graft histology, function, and survival. In a small random-
ized study, Rush et al [19, 20] demonstrated that recogni-
tion and treatment of subclinical rejection episodes can
lead to a significant decrease in late acute rejection rate, a
reduced chronic tubulointerstitial score at 6 months, and
better renal function at 12 months as compared to non-
treatment. Hence, the importance of performing protocol
graft biopsies is more and more emphasized [9, 11, 14, 21].
Acute cellular rejection is due to a cell-mediated im-
mune response consisting of both T-helper cell-mediated
delayed-type hypersensitivity and cytotoxicity mediated
by granzyme-positive T cells [3, 16]. Presumably, the
expression of proapoptotic genes promotes events that
lead to graft rejection, while expression of antiapop-
totic (protective) genes suppresses those events and
thus contributes to sustained graft survival. Granzyme B
plays a key role in induction of apoptosis which causes
tubular cell destruction [1, 2, 18]. Once released into
cytoplasm, granzyme B can initiate apoptosis through
different pathways: by direct or caspase 8–mediated
cleavage of caspase 3; by activation of proapoptotic Bcl-2
family member Bid and subsequent induction of mito-
chondrial collapse leading to release of cytochrome c;
by cleavage of the inhibitor of caspase-activated de-
oxynuclease, resulting in endonuclease activity; and by
inducing caspase-independent DNA fragmentation [22].
Up to recently, the presence of a granzyme B–positive
cytotoxic T-cell infiltrate was considered to be indica-
tive for acute allograft rejection. In this regard, our find-
ing of the presence of a cytotoxic infiltrate expressing
granzyme B in the allograft of patients with a stable renal
graft function supports the idea that the potential de-
structive forces may not be different from each other
in acute and subclinical rejections. However, in case of
subclinical rejection, these cytotoxic infiltrates are appar-
ently kept silent among others by the concomitant high
expression of the specific granzyme B inhibitor PI-9 by
tubular epithelial cells. PI-9 has also some other func-
tions. It inhibits not only granzyme B but also some other
caspases, like caspase 1, thereby inhibiting interleukin
(IL)-1b production. In addition, it inhibits elastase ac-
tivity which may account for the protective effect on
endothelial cells against elastase-mediated degradation
during neutrophil extravasation [23]. These antiapoptotic
and anti-inflammatory effects render PI-9 a particular
role in regulation of inflammation and apoptosis. Recent
data demonstrate that expression levels of PI-9 are corre-
lates of granzyme B levels in kidney transplant recipients.
Muthkumar et al [24] showed an increased expression of
PI-9 mRNA level in urinary cells of patients with acute
rejection versus no rejection which was linearly corre-
lated with granzyme B mRNA level. However, they did
not study patients with subclinical rejection, nor did they
detect PI-9 at protein level. It has been shown that PI-
9 gene expression is induced by proinflammatory agents
such as lipopolysaccharide (LPS) and the cytokines IL-
1b and tumor necrosis factor-a (TNF-a) [25]. Thus, it
seems that PI-9 has a central role in modulating inflamma-
tory processes, such as inhibition of IL-1b activation, and
apoptosis, by inhibition of granzyme B. The inhibition of
granzyme B–mediated toxicity by high levels of PI-9 can
apparently be seen as one of the factors leading to a stable
renal function early after transplantation, but is probably
unable to prevent long-term effects of these episodes of
immune mediated graft injury. Better understanding of
the immunopathologic mechanisms underlying subclini-
cal rejection episodes is necessary to identify new ther-
apeutic approaches in prevention and treatment of de-
structive injury to graft tissue. Induction of up-regulated
PI-9 in renal tubular cells might be considered as a new
strategy to confer resistance against cytotoxic effects of
granzyme B–mediated effects, eventually leading to bet-
ter graft survival.
Concerning other potential factors playing a role in
acute rejection episodes one can conclude that data re-
garding the importance of the CD95 pathway in the
pathophysiology of acute allograft rejection are contro-
versial up to now. During acute rejection, both an in-
crease and a decrease in expression of CD95 in human
renal tubular epithelial cells have been described [26–
28]. The role and engagement of CD95-CD95 ligand
pathway inhibitor FLIP during acute rejection in renal
transplant recipients is not clarified yet. Other mecha-
nisms for cells to escape immune-mediated cytotoxic-
ity, like expression of regulatory proteins to confer re-
sistance to CD95-mediated apoptosis and major histo-
compatability complex (MHC) I down-regulation, have
been described previously [29, 30]. More recently, sev-
eral other molecules with cytoprotective and antiapop-
totic functions like heme oxygenase-1 (HO-1) and A20, a
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cytoplasmic zinc finger protein, have received consider-
able attention as potential therapeutic targets in allograft
rejection. Expression of these protective genes A20, HO-
1, and Bcl-xL in rodent allo- and xenografts indeed cor-
relates with long-term survival [31, 32]. Analyzing the ex-
pression of these genes in 31 renal allograft biopsies from
patients with suspected rejection showed up-regulation
of A20 and HO-1 [33]. These molecules were localized
mainly in endothelial, smooth muscle, and infiltrating
mononuclear cells but not in tubular epithelial cells.
CONCLUSION
Our findings support the idea that increased expres-
sion of the granzyme B inhibitor PI-9 in human renal
allografts provides an explanation for the silence of his-
tologically apparent cytotoxic infiltrates in subclinical re-
jections pointing out a way to resist a fatal attraction.
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